BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 8144942)

  • 1. In vivo or in vitro anti-CD3 epsilon chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice.
    Blazar BR; Taylor PA; Vallera DA
    J Immunol; 1994 Apr; 152(7):3665-74. PubMed ID: 8144942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonmitogenic anti-CD3F(ab')2 fragments inhibit lethal murine graft-versus-host disease induced across the major histocompatibility barrier.
    Blazar BR; Taylor PA; Snover DC; Bluestone JA; Vallera DA
    J Immunol; 1993 Jan; 150(1):265-77. PubMed ID: 8417127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of anti-CD3 epsilon F(ab')2 fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation.
    Johnson BD; McCabe C; Hanke CA; Truitt RL
    J Immunol; 1995 May; 154(10):5542-54. PubMed ID: 7730653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CD3 epsilon F(ab')2 fragments inhibit T cell expansion in vivo during graft-versus-host disease or the primary immune response to nominal antigen.
    Blazar BR; Jenkins MK; Taylor PA; White J; Panoskaltsis-Mortari A; Korngold R; Vallera DA
    J Immunol; 1997 Dec; 159(12):5821-33. PubMed ID: 9550378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo administration of anti-CD3 monoclonal antibodies or immunotoxins in murine recipients of allogeneic T cell-depleted marrow for the promotion of engraftment.
    Blazar BR; Hirsch R; Gress RE; Carroll SF; Vallera DA
    J Immunol; 1991 Sep; 147(5):1492-503. PubMed ID: 1831826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
    Drobyski WR; Majewski D; Ozker K; Hanson G
    J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
    Johnson BD; Becker EE; LaBelle JL; Truitt RL
    J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells.
    Blazar BR; Sharpe AH; Taylor PA; Panoskaltsis-Mortari A; Gray GS; Korngold R; Vallera DA
    J Immunol; 1996 Oct; 157(8):3250-9. PubMed ID: 8871619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of T cell costimulation by VCAM-1 prevents murine graft-versus-host disease across minor histocompatibility barriers.
    Schlegel PG; Vaysburd M; Chen Y; Butcher EC; Chao NJ
    J Immunol; 1995 Oct; 155(8):3856-65. PubMed ID: 7561092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amelioration of acute graft-versus-host disease and re-establishment of tolerance by short-term treatment with an anti-TCR antibody.
    Maeda T; Eto M; Lin T; Nishimura Y; Kong YY; Nomoto K; Nomoto K
    J Immunol; 1994 Nov; 153(9):4311-20. PubMed ID: 7930630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
    Li JM; Gorechlad J; Larsen CP; Waller EK
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FK506 inhibits graft-versus-host disease and bone marrow graft rejection in murine recipients of MHC disparate donor grafts by interfering with mature peripheral T cell expansion post-transplantation.
    Blazar BR; Taylor PA; Fitzsimmons WE; Vallera DA
    J Immunol; 1994 Aug; 153(4):1836-46. PubMed ID: 7519216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens.
    Berger M; Wettstein PJ; Korngold R
    Transplantation; 1994 Apr; 57(7):1095-102. PubMed ID: 7909395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A correlation between conditioning and engraftment in recipients of MHC-mismatched T cell-depleted murine bone marrow transplants.
    Soderling CC; Song CW; Blazar BR; Vallera DA
    J Immunol; 1985 Aug; 135(2):941-6. PubMed ID: 3891856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of lethal graft-versus-host disease in mice by monoclonal antibodies directed to T cells or their subsets. II. Differential effectiveness of IgG2a and IgG2b isotypes of anti-CD3 and anti-CD4 moAb.
    Knulst AC; Noort WA; Tibbe GJ; Benner R; Savelkoul HF
    Bone Marrow Transplant; 1994 Oct; 14(4):535-43. PubMed ID: 7858528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiotherapy in mice with yttrium-90-labeled anti-Ly1 monoclonal antibody: therapy of established graft-versus-host disease induced across the major histocompatibility barrier.
    Vallera DA; Schmidberger H; Buchsbaum DJ; Everson P; Snover DC; Blazar BR
    Cancer Res; 1991 Apr; 51(7):1891-7. PubMed ID: 2004372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of lethal graft-versus-host disease by anti-CD137 monoclonal antibody in mice prone to chronic graft-versus-host disease.
    Kim W; Kim J; Jung D; Kim H; Choi HJ; Cho HR; Kwon B
    Biol Blood Marrow Transplant; 2009 Mar; 15(3):306-14. PubMed ID: 19203721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of lethal graft-vs.-host disease by a single low dose injection of anti-T cell monoclonal antibody to the allograft recipients.
    Knulst AC; Bril-Bazuin C; Benner R
    Eur J Immunol; 1991 Jan; 21(1):103-7. PubMed ID: 1671355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of lethal graft-versus-host disease in mice by monoclonal antibodies directed against T cells or their subsets. I. Evidence for the induction of a state of tolerance based on suppression.
    Knulst AC; Tibbe GJ; Noort WA; Bril-Bazuin C; Benner R; Savelkoul HF
    Bone Marrow Transplant; 1994 Mar; 13(3):293-301. PubMed ID: 8199571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A subset of asialo GM1+ cells play a protective role in the occurrence of graft-versus-host disease in mice.
    De Ruysscher D; Sobis H; Vandeputte M; Waer M
    J Immunol; 1991 Jun; 146(12):4065-70. PubMed ID: 1828259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.